13th Nov 2015 07:00
Horizon Discovery Group plc
Director/PDMR Shareholding
Cambridge, UK, 13 November 2015: Horizon Discovery Group plc (LSE: HZD) ("Horizon" or "the Company"), the international life science company supplying genomics research tools and services that power genomics research and the development of personalized medicines, today announces that, on 12 November 2015, certain directors of the Company purchased ordinary shares of 1 penny each in the capital of the Company ("Ordinary Shares") at 141.0 pence per Ordinary Share. Details of the purchase of Ordinary Shares, and each Director's resulting beneficial interest in the Company's issued share capital, are shown below:
Name of Director | Number of Ordinary Shares purchased | Resulting number of Ordinary Shares held | Resulting number of Ordinary Shares held as a percentage of Company's issued share capital |
Mr Grahame Cook | 42,250 | 42,250 | 0.04% |
Dr Darrin Disley | 7,000 | 689,523 | 0.73% |
Dr Ian Gilham | 17,600 | 31,488 | 0.03% |
Dr Vishal Gulati | 14,100 | 14,100 | 0.01% |
Dr Jonathan Milner* | 7,500 | 9,699,680 | 10.31% |
Mrs Susan Searle | 17,500 | 37,500 | 0.04% |
Mr Richard Vellacott | 7,000 | 7,000 | 0.01% |
*Mr Milner's purchase of Ordinary Shares was made by his wife, and is therefore considered a beneficial holding of Mr Milner's
ENDS
For further information from Horizon Discovery Group plc, please contact:
Consilium Strategic Communications (Financial Media and Investor Relations)
Amber Fennell / Jessica Hodgson / Matthew Neal / Laura Thornton
Tel: +44 (0) 20 3709 5701
Email: [email protected]
Zyme Communications (Trade and Regional Media)
Katie Odgaard
Tel: +44 (0)7787 502 947
Email: [email protected]
Panmure Gordon (UK) Limited (NOMAD)
Corporate Finance: Freddy Crossley / Fabien Holler / Duncan Monteith
Broking: Tom Salvesen
Tel: +44 20 7886 2500
About Horizon Discovery Group plc www.horizondiscovery.com/
Horizon is a revenue-generating life science group supplying research tools to organisations engaged in translational genomics research and the development of personalised medicines. Horizon has a diverse and international customer base of over 1,200 organisations across more than 50 countries, including major pharmaceutical, biotechnology and diagnostic companies as well as leading academic research centers. The Group supplies its products and services into multiple markets, estimated to total in excess of £29 billion by 2015.
Horizon's core capabilities are built around its proprietary translational genomics platform, a high-precision and flexible suite of gene editing tools able to alter almost any endogenous gene sequence of human or mammalian cell-lines. Horizon offers over 20,000 catalogue products, almost all of which are based on the application of gene editing to generate cell lines that accurately model the disease-causing mutations found in genetically based diseases. These 'patients-in-a-test-tube' are being used by customers to identify the effect of individual or compound genetic mutations on drug activity, patient responsiveness, and resistance, which may lead to the successful prediction of which patient sub-groups will respond to currently available and future drug treatments.
In addition, Horizon provides custom cell line and in vivo model generation services for research and bioproduction applications, quantitative molecular reference standards, in vivo disease models, and contract research and custom screening services.
Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange's AIM market under the ticker "HZD", for further information please visit: www.horizondiscovery.com.
Related Shares:
HZD.L